Development and Validation of a Risk Stratification Model Using Disease Severity Hierarchy for Mortality or Major Cardiovascular Event.


Journal

JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235

Informations de publication

Date de publication:
01 07 2020
Historique:
entrez: 18 7 2020
pubmed: 18 7 2020
medline: 29 12 2020
Statut: epublish

Résumé

Clinical domain knowledge about diseases and their comorbidities, severity, treatment pathways, and outcomes can facilitate diagnosis, enhance preventive strategies, and help create smart evidence-based practice guidelines. To introduce a new representation of patient data called disease severity hierarchy that leverages domain knowledge in a nested fashion to create subpopulations that share increasing amounts of clinical details suitable for risk prediction. This retrospective cohort study included 51 969 patients aged 45 to 85 years, with 10 674 patients who received primary care at the Mayo Clinic between January 2004 and December 2015 in the training cohort and 41 295 patients who received primary care at Fairview Health Services from January 2010 to December 2017 in the validation cohort. Data were analyzed from May 2018 to December 2019. Several binary classification measures, including the area under the receiver operating characteristic curve (AUC), Gini score, sensitivity, and positive predictive value, were used to evaluate models predicting all-cause mortality and major cardiovascular events at ages 60, 65, 75, and 80 years. The mean (SD) age and proportions of women and white individuals were 59.4 (10.8) years, 6324 (59.3%) and 9804 (91.9%), respectively, in the training cohort and 57.4 (7.9) years, 21 975 (53.1%), and 37 653 (91.2%), respectively, in the validation cohort. During follow-up, 945 patients (8.9%) in the training cohort died, while 787 (7.4%) had major cardiovascular events. Models using the new representation achieved AUCs for predicting death in the training cohort at ages 60, 65, 75, and 80 years of 0.96 (95% CI, 0.94-0.97), 0.96 (95% CI, 0.95-0.98), 0.97 (95% CI, 0.96-0.98), and 0.98 (95% CI, 0.98-0.99), respectively, while standard methods achieved modest AUCs of 0.67 (95% CI, 0.55-0.80), 0.66 (95% CI, 0.56-0.79), 0.64 (95% CI, 0.57-0.71), and 0.63 (95% CI, 0.54-0.70), respectively. In this study, the proposed patient data representation accurately predicted the age at which a patient was at risk of dying or developing major cardiovascular events substantially better than standard methods. The representation uses known relationships contained in electronic health records to capture disease severity in a natural and clinically meaningful way. Furthermore, it is expressive and interpretable. This novel patient representation can help to support critical decision-making, develop smart guidelines, and enhance health care and disease management by helping to identify patients with high risk.

Identifiants

pubmed: 32678448
pii: 2768345
doi: 10.1001/jamanetworkopen.2020.8270
pmc: PMC7368174
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

e208270

Subventions

Organisme : NCATS NIH HHS
ID : UL1 TR002494
Pays : United States

Références

J Manag Care Pharm. 2010 Apr;16(3):185-95
pubmed: 20331323
Int Stat Rev. 2017 Aug;85(2):185-203
pubmed: 29307954
Sci Rep. 2016 Dec 19;6:39433
pubmed: 27991583
Mayo Clin Proc. 1996 Mar;71(3):266-74
pubmed: 8594285
Stat Med. 2012 Nov 30;31(27):3320-7
pubmed: 22531976
BMC Med Res Methodol. 2017 Apr 7;17(1):53
pubmed: 28388943
J Gen Intern Med. 2007 Dec;22 Suppl 3:391-5
pubmed: 18026807
Med Care. 2009 Jul;47(7):813-21
pubmed: 19536031
Prev Chronic Dis. 2014 Apr 17;11:E62
pubmed: 24742395
Diabetes Care. 2019 Jan;42(Suppl 1):S13-S28
pubmed: 30559228
J Stat Softw. 2011 Mar;39(5):1-13
pubmed: 27065756
BMJ. 2016 Jan 25;352:i6
pubmed: 26810254
BMC Med Inform Decis Mak. 2008 Nov 26;8:53
pubmed: 19036144
J Gerontol A Biol Sci Med Sci. 1998 Sep;53(5):M337-43
pubmed: 9754138
NCHS Data Brief. 2012 Jul;(100):1-8
pubmed: 23101759
Med Care Res Rev. 2011 Aug;68(4):387-420
pubmed: 21813576
Expert Rev Pharmacoecon Outcomes Res. 2015;15(5):823-32
pubmed: 26400220
J Biomed Inform. 2019 Jan;89:56-67
pubmed: 30189255
Arch Intern Med. 2002 Nov 11;162(20):2269-76
pubmed: 12418941
Am J Manag Care. 2011 Feb;17(2):118-22
pubmed: 21473661
BMC Health Serv Res. 2010 May 27;10:140
pubmed: 20507593
Am J Manag Care. 2013 Sep;19(9):725-32
pubmed: 24304255

Auteurs

Che Ngufor (C)

Division of Digital Health Science, Department of Health Science Research, Mayo Clinic, Rochester, Minnesota.
The Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota.

Pedro J Caraballo (PJ)

Division of Digital Health Science, Department of Health Science Research, Mayo Clinic, Rochester, Minnesota.
Division of General Internal Medicine, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.

Thomas J O'Byrne (TJ)

Division of Healthcare Policy and Research, Department of Health Science Research, Mayo Clinic, Rochester, Minnesota.

David Chen (D)

Division of Digital Health Science, Department of Health Science Research, Mayo Clinic, Rochester, Minnesota.

Nilay D Shah (ND)

The Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota.
Division of Healthcare Policy and Research, Department of Health Science Research, Mayo Clinic, Rochester, Minnesota.

Lisiane Pruinelli (L)

University of Minnesota School of Nursing, Minneapolis.

Michael Steinbach (M)

Department of Computer Science and Engineering, University of Minnesota, Minneapolis.

Gyorgy Simon (G)

Division of General Internal Medicine, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
Institute for Health Informatics, University of Minnesota, Minneapolis.
Department of Medicine, University of Minnesota, Minneapolis.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH